Dr. Patel on the FDA Approval of Durvalumab in NSCLC
February 17th 2018
Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non